Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the chemical formula C23H26ClN5O3 and a molecular weight of approximately 455.9 g/mol[1][4]. It belongs to the class of N‑phenylureas[4]. The compound is listed in chemical and pharmaceutical databases (e.g., PubChem CID: 6540299, DrugBank ID: DB08095, ChEMBL ID: CHEMBL379760)[1][3][4]. There are no approved medical indications or clinical trials associated with this molecule as of June 2025[2][4]. Its mechanism of action and biological targets have not been characterized in public sources. It is considered an experimental research compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-(2-chlorophenyl)-1-(2-{[(1S)-2-hydroxy-1,2-dimethylpropyl]amino}pyrimidin-4-yl)-1-(4-methoxyphenyl)urea.